Polysulfated Hyaluronan GlycoMira-1111 Inhibits Elastase and Improves Rheology in Cystic Fibrosis Sputum.
Adult
Anti-Inflammatory Agents
/ therapeutic use
Cystic Fibrosis
/ drug therapy
DNA
/ metabolism
Deoxyribonuclease I
/ metabolism
Female
Heparin
/ therapeutic use
Humans
Hyaluronic Acid
/ therapeutic use
Leukocyte Elastase
/ metabolism
Male
Recombinant Proteins
/ metabolism
Rheology
Sputum
/ drug effects
cystic fibrosis
dornase alfa
heparin
hyaluronan
neutrophil elastase
Journal
American journal of respiratory cell and molecular biology
ISSN: 1535-4989
Titre abrégé: Am J Respir Cell Mol Biol
Pays: United States
ID NLM: 8917225
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
pubmed:
3
12
2020
medline:
23
2
2021
entrez:
2
12
2020
Statut:
ppublish
Résumé
Cystic fibrosis (CF) lung disease is marked by high concentrations of neutrophil elastase (NE) and DNA polymers; both factors contribute to airway disease. Although inhaled recombinant human dornase alfa reduces the frequency of CF pulmonary exacerbations, it also increases free NE activity in the sputum. There are no approved anti-NE therapies for patients with CF. We investigated whether synthetic, low-molecular weight polysulfated hyaluronan GlycoMira-1111 (GM-1111) would be effective as an anti-NE drug using
Identifiants
pubmed: 33264072
doi: 10.1165/rcmb.2020-0157OC
pmc: PMC7874391
doi:
Substances chimiques
Anti-Inflammatory Agents
0
Recombinant Proteins
0
Hyaluronic Acid
9004-61-9
Heparin
9005-49-6
DNA
9007-49-2
Deoxyribonuclease I
EC 3.1.21.1
dornase alfa
EC 3.1.21.1
Leukocyte Elastase
EC 3.4.21.37
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
260-267Subventions
Organisme : NIAID NIH HHS
ID : R44 AI126987
Pays : United States
Références
Int Forum Allergy Rhinol. 2017 Feb;7(2):177-184
pubmed: 27863138
Antibiotics (Basel). 2015 Jan 15;4(1):62-75
pubmed: 27025615
Int J Biochem Cell Biol. 2008;40(6-7):1238-45
pubmed: 18395488
Pediatr Pulmonol. 2019 Dec;54(12):1968-1973
pubmed: 31468741
N Engl J Med. 2013 May 23;368(21):1963-70
pubmed: 23692169
J Biol Chem. 2018 Aug 10;293(32):12480-12490
pubmed: 29903912
Am J Physiol. 1999 May;276(5):L835-43
pubmed: 10330040
Am J Respir Crit Care Med. 1998 Mar;157(3 Pt 1):710-4
pubmed: 9517580
ACS Appl Mater Interfaces. 2019 May 29;11(21):18995-19005
pubmed: 31058483
Am J Respir Crit Care Med. 2020 Jan 15;201(2):141-147
pubmed: 31626562
Am J Physiol Cell Physiol. 2010 Jul;299(1):C97-110
pubmed: 20375277
J Clin Invest. 2002 Mar;109(5):661-70
pubmed: 11877474
J Pharmacol Exp Ther. 1997 Jul;282(1):208-19
pubmed: 9223556
Mediators Inflamm. 2015;2015:293053
pubmed: 26185359
Am J Physiol Lung Cell Mol Physiol. 2005 Oct;289(4):L599-605
pubmed: 15964901
Am J Physiol Lung Cell Mol Physiol. 2007 Nov;293(5):L1240-9
pubmed: 17827252
Am J Respir Cell Mol Biol. 2017 Jan;56(1):90-98
pubmed: 27585400
Am J Respir Cell Mol Biol. 2014 Apr;50(4):684-9
pubmed: 24325600
Eur Respir J. 2019 Jul 11;54(1):
pubmed: 31023850
Thorax. 2018 Feb;73(2):134-144
pubmed: 28916704
Am J Respir Crit Care Med. 2012 Nov 1;186(9):857-65
pubmed: 22904182
PLoS One. 2018 Sep 25;13(9):e0204709
pubmed: 30252910
J Cyst Fibros. 2015 Sep;14(5):587-93
pubmed: 25682700
J Cyst Fibros. 2015 Jul;14(4):419-30
pubmed: 25814049
Curr Opin Pharmacol. 2019 Jun;46:50-54
pubmed: 31009826
Medicine (Baltimore). 2017 Nov;96(47):e8423
pubmed: 29381919
Chest. 2018 Aug;154(2):370-377
pubmed: 29559310
PLoS One. 2014 Jan 03;9(1):e82297
pubmed: 24404129
PLoS One. 2017 Aug 24;12(8):e0183542
pubmed: 28837619
J Med Chem. 2019 Jun 13;62(11):5501-5511
pubmed: 31074986
Biochemistry. 2006 Aug 1;45(30):9104-20
pubmed: 16866356
PLoS One. 2016 Jun 16;11(6):e0157310
pubmed: 27308827
Ann N Y Acad Sci. 2007 Sep;1112:140-53
pubmed: 17496063